PATIENT-REPORTED OUTCOMES FROM THE PHASE 3 ENGOT-CX12/GOG-3057/INNOVATV 301 TRIAL OF TISOTUMAB VEDOTIN AS SECOND/THIRD-LINE TREATMENT FOR RECURRENT OR METASTATIC CERVICAL CANCER | Publicación